You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

S1P Receptor Modulators in Multiple Sclerosis: Who, When, and Why?

  • Authors: Frauke Zipp, MD
  • CPD Released: 3/21/2022
  • Valid for credit through: 3/21/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 1.00 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of neurologists, primary care physicians, and nurses practicing in Europe, the Middle East, and North Africa.

The goal of this activity is that clinicians will have increased knowledge of the role of the multiple sphingosine-1-phosphate (S1P) receptor modulators in early multiple sclerosis (MS).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Rationale for using an S1P receptor modulator for patients with MS, based on mechanism of action
    • Clinical data on the use of S1P receptor modulators in patients with MS
  • Have greater competence related to
    • Selecting an S1P receptor modulator based on patient and disease characteristics


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Disclosures for additional planners can be found here.


Faculty

  • Frauke Zipp, MD

    Professor of Neurology
    Director of Department of Neurology
    Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI)
    Rhine Main Neuroscience Network (rmn²)
    Johannes Gutenberg University Medical Center
    Mainz, Germany

    Disclosures

    Grants for clinical research from: Biogen; BMBF; Bristol Myers Squibb; DFG; Janssen; Merck; MPI; Novartis; PMSA; Roche; Sandoz
    Advisor or consultant for: Biogen; BMBF; Bristol Myers Squibb; DFG; Janssen; Merck; MPI; Novartis; PMSA; Roche; Sandoz

Editors

  • Leanne Fairley, BJ Hon

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Leanne Fairley, BJ Hon, has disclosed no relevant financial relationships.

  • Kevan Chambers, FRSA, MRSB

    Medical Writer, WebMD Global, LLC

    Disclosures

    Disclosure: Kevan Chambers, FRSA, MRSB, has disclosed no relevant financial relationships.

Compliance Reviewer

  • Susan L. Smith, MN, PhD

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Susan L. Smith, MN, PhD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

S1P Receptor Modulators in Multiple Sclerosis: Who, When, and Why?

Authors: Frauke Zipp, MDFaculty and Disclosures

CPD Released: 3/21/2022

Valid for credit through: 3/21/2023

processing....

The following cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short posttest assessment based on the material presented.

CASE 1: PATIENT HISTORY

Carly is a 29-year-old woman who was recently referred to a neurologist because she had experienced pain and tingling in her legs over the course of a week. While walking, she had also noticed some weakness in her legs, which got worse over a few days.

Carly is married with 2 children, ages 2 and 4 years, and she works part-time from home as a bookkeeper. During her initial visit with the neurologist, she also commented, "I've begun to feel tired all of the time lately -- although that could, of course, be due to working and taking care of 2 toddlers who seem to go nonstop!"

Based on Carly's symptoms, a physical exam, and a fatigue workup, the neurologist suspected that Carly had developed relapsing-remitting multiple sclerosis (RRMS). He determined that during her recent relapse, she had an Expanded Disability Status Scale (EDSS) score of 3, based on the apparent presence of paraparesis with Babinski sign, paresthesia, and fatigue. After the relapse, her EDSS score was 1, with some residual tingling.

He ordered a gadolinium (Gd)-enhanced magnetic resonance imaging (MRI), which showed 3 periventricular lesions, 2 spinal lesions, 1 cervical lesion, and 1 thoracic Gd-enhancing lesion. Carly is returning today to discuss the results of those tests, confirming the diagnosis of RRMS.

  • Print